ClinicalTrials.Veeva

Menu

Thoracic Paravertebral Block for Postoperative Pain Management After VATS

K

King Hussein Cancer Center

Status

Completed

Conditions

Pain, Postoperative

Treatments

Drug: 0.4 ml/kg of 0.5% bupivacaine

Study type

Interventional

Funder types

Other

Identifiers

NCT06689358
22 KHCC 158

Details and patient eligibility

About

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS).

Full description

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS). Adult patients scheduled for elective VATS who meet the eligibility criteria will be randomized to either Arm:

Arm 1: General anesthesia with TPVB;

Arm 2: General anesthesia alone (control group).

Primary Outcome: to assess Opioid requirement in the PACU

Enrollment

81 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients scheduled for elective VATS, ASA physical status II-III, BMI 19-40.

Exclusion criteria

  • Patient refusal, coagulation disorders, contraindications to TPVB, chronic analgesic use, mental illness

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

81 participants in 2 patient groups

General anesthesia with TPVB
Experimental group
Description:
0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
Treatment:
Drug: 0.4 ml/kg of 0.5% bupivacaine
General anesthesia alone (control group).
No Intervention group
Description:
General anesthesia SOC alone

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems